Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Merck ... HispanicBusiness.com ... monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab ... |
